Seelos Therapeutics reports progress on several of its drug R&D initiatives, including preparing for a Phase IIb/Phase III trial of SLS-005 for ALS.

Enveric Biosciences announces the filing of its 10th patent application for its tryptamine-based molecules.

Revitalist and Pharmather to collaborate on novel and standardized treatment protocols for for ketamine-based psychotherapy.

MINDCURE announces new formulations for its proprietary synthetic ibogaine, supported by a new patent application.

MindMed releases a peer-reviewed study that confirms the similar psychoactive effects of psilocybin and Lysergic Acid Diethylamide (LSD).

MindMed announced the peer-reviewed publication of a study directly comparing the acute effects of LSD and psilocybin in healthy subjects.

Field Trip Health announces a strategic partnership with Cerebral, “the fastest growing online mental health platform”.

Novamind reports 32% q-o-q revenue growth, up to CAD $2.45 million in its latest quarter. Cash balance of ~CAD$8 million including post-period financing.

Mydecine prepares to submit its IND and application for Breakthrough Therapy Status for smoking cessation after successful meeting with FDA.

Red Light Holland reports quarterly revenue growth of 28% and gross profit growth of 48% for Q3 of fiscal 2022. Strong cash position of CAD$27.3 million.